# Senores Pharmaceuticals (NSE: SENORES) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SENORES · Pivot · prices to 22 Oct 2026

Senores Pharmaceuticals (NSE: SENORES) closed at ₹1,233.30 on 22 Oct 2026, up 0.35% on the day. With a market capitalisation of ₹5,680 Cr, it ranks 740th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 46.7× trailing earnings, against a return on equity of 7.4% in FY25. Over the past year the share price has risen 71.0%. Its 52-week range is ₹706.00 (23 Mar 2026) to ₹1,599.00 (24 Aug 2026); the last close is 22.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹180 Cr (+38.3% year on year) and net profit ₹30 Cr (+43.8%), on a consolidated basis. Promoters held 45.82% of the company as of 30 Jun 2026; 2.81% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,233.30 |
| Market cap | ₹5,680 Cr |
| P/E (trailing) | 46.7 |
| ROE | 7.4% (FY25) |
| ROCE | 9.3% (FY25) |
| Debt to equity | 0.39 |
| 52-week high | ₹1,599.00 (24 Aug 2026) |
| 52-week low | ₹706.00 (23 Mar 2026) |
| 1-year return | +71.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹180 Cr | +38.3% | ₹30 Cr | +43.8% | ₹6.61 |
| Q4 FY26 | ₹175 Cr | +53.4% | ₹37 Cr | +104.1% | ₹7.96 |
| Q3 FY26 | ₹165 Cr | +60.0% | ₹34 Cr | +104.4% | ₹7.29 |
| Q2 FY26 | ₹153 Cr | +56.1% | ₹30 Cr | +131.0% | ₹6.54 |
| Q1 FY26 | ₹130 Cr | +16,187.5% | ₹21 Cr | +19,154.5% | ₹4.60 |
| Q4 FY25 | ₹114 Cr | −46.8% | ₹18 Cr | −45.0% | ₹3.81 |
| Q3 FY25 | ₹103 Cr | +30.9% | ₹16 Cr | +130.8% | ₹5.04 |
| Q2 FY25 | ₹98 Cr | — | ₹13 Cr | — | ₹3.92 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹398 Cr | ₹58 Cr |
| FY24 | ₹215 Cr | ₹33 Cr |
| FY23 | ₹35 Cr | ₹8 Cr |
| FY22 | ₹14 Cr | ₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 45.82%
- Foreign institutions: 6.62%
- Domestic institutions: 9.77%
- Non-institutions: 37.79%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |
| [Nephrocare Health Services](https://app.pivotnow.in/stock/NEPHROPLUS) | ₹599.90 | ₹6,019 Cr | 74.1 | — |
| [Sun Pharma Advanced Research Company](https://app.pivotnow.in/stock/SPARC) | ₹176.82 | ₹5,738 Cr | 3.7 | — |
| [Innova Captab](https://app.pivotnow.in/stock/INNOVACAP) | ₹983.60 | ₹5,629 Cr | 40 | — |
| [FDC](https://app.pivotnow.in/stock/FDC) | ₹339.20 | ₹5,523 Cr | — | — |
| [IOL Chemicals and Pharmaceuticals](https://app.pivotnow.in/stock/IOLCP) | ₹173.27 | ₹5,086 Cr | 36.9 | — |

## Questions and answers

### What is the share price of Senores Pharmaceuticals today?

Senores Pharmaceuticals (NSE: SENORES) last closed at ₹1,233.30 on 22 Oct 2026. Its 52-week high is ₹1,599.00 and its 52-week low is ₹706.00.

### What is the market cap of Senores Pharmaceuticals?

Senores Pharmaceuticals' market capitalisation is ₹5,680 Cr (₹5,680 Cr) at the 22 Oct 2026 close, ranking 740th among the NSE companies Pivot tracks.

### What is the P/E ratio of Senores Pharmaceuticals?

Senores Pharmaceuticals trades at a trailing P/E of 46.7. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 36.9.

### What is the ROE and ROCE of Senores Pharmaceuticals?

Return on equity was 7.4% in FY25 and return on capital employed was 9.3% in FY25 (consolidated figures).

### Is Senores Pharmaceuticals a debt-free company?

No. Senores Pharmaceuticals' debt-to-equity ratio was 0.39 in FY25, with total debt of ₹162 Cr.

### What were Senores Pharmaceuticals' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Senores Pharmaceuticals reported revenue of ₹180 Cr, +38.3% year on year, and net profit of ₹30 Cr, +43.8% year on year.

### How has Senores Pharmaceuticals stock performed over the last year?

Senores Pharmaceuticals' share price has risen 71.0% over the past year, −11.4% over three months and −11.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Senores Pharmaceuticals?

As of 30 Jun 2026: promoters 45.82%, foreign institutions 6.62%, domestic institutions 9.77%, non-institutions 37.79%. 2.81% of promoter shares were pledged.

### Who are Senores Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Senores Pharmaceuticals by market cap are Kovai Medical Center & Hospital, Nephrocare Health Services, Sun Pharma Advanced Research Company, Innova Captab, FDC and IOL Chemicals and Pharmaceuticals.

### Is Senores Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Senores Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SENORES against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.